Targovax AS
Testing a peptide vaccine against pancreatic cancer
This article was originally published in Start Up
Executive Summary
Dendreon’s prostate-cancer treatment Provenge demonstrated that the concept of rallying the body’s immune system to fight cancer actually can work. Norwegian start-up Targovax AS is one of many companies working to commercialize peptide vaccines intended to rouse the immune system and train it to recognize cancer. Its pancreatic cancer treatment is injected into the skin, so that peptides can be taken up by dendritic cells, which then carry the peptides off to the lymph nodes and present them to T cells, which then enter the body’s circulation with a potential to kill, or stimulate the killing of, cancer cells.
You may also be interested in...
Vaccine Investment Gets A Shot In The Arm
The vaccine industry has had its ups and downs the last two decades, as public opinion and investor perception has influenced both the use and production of these preventative medicines. It’s traditionally been a difficult space for smaller companies due to the financial hurdles, but a handful of start-ups, including TremRx, Selecta Biosciences Inc., Genocea Biosciences Inc. and Imaxio SA, all profiled in this issue, are banking on progress in delivery and development technology to help them raise financing for their vaccines programs.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.